nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—SLC22A2—Progesterone—uterine cancer	0.0641	0.119	CbGbCtD
Imatinib—SLC22A1—Progesterone—uterine cancer	0.0557	0.104	CbGbCtD
Imatinib—ABCG2—Dactinomycin—uterine cancer	0.0375	0.0699	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.035	0.0651	CbGbCtD
Imatinib—CYP3A7—Progesterone—uterine cancer	0.035	0.0651	CbGbCtD
Imatinib—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0266	0.0494	CbGbCtD
Imatinib—CYP3A5—Progesterone—uterine cancer	0.0262	0.0488	CbGbCtD
Imatinib—ABCG2—Carboplatin—uterine cancer	0.0252	0.047	CbGbCtD
Imatinib—ABCG2—Etoposide—uterine cancer	0.0212	0.0394	CbGbCtD
Imatinib—CYP2C19—Progesterone—uterine cancer	0.0212	0.0394	CbGbCtD
Imatinib—PTGS1—Etoposide—uterine cancer	0.0196	0.0364	CbGbCtD
Imatinib—CYP1A2—Progesterone—uterine cancer	0.0195	0.0363	CbGbCtD
Imatinib—CYP2C9—Progesterone—uterine cancer	0.0176	0.0327	CbGbCtD
Imatinib—ABCB1—Progesterone—uterine cancer	0.0171	0.0318	CbGbCtD
Imatinib—CYP2D6—Progesterone—uterine cancer	0.0161	0.0299	CbGbCtD
Imatinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0154	0.0287	CbGbCtD
Imatinib—ABCG2—Doxorubicin—uterine cancer	0.0145	0.0269	CbGbCtD
Imatinib—ABCB1—Dactinomycin—uterine cancer	0.0135	0.0252	CbGbCtD
Imatinib—CYP3A5—Etoposide—uterine cancer	0.0117	0.0219	CbGbCtD
Imatinib—CYP3A4—Progesterone—uterine cancer	0.0102	0.019	CbGbCtD
Imatinib—CYP1A2—Etoposide—uterine cancer	0.00874	0.0163	CbGbCtD
Imatinib—ABCB1—Etoposide—uterine cancer	0.00764	0.0142	CbGbCtD
Imatinib—ABCB1—Doxorubicin—uterine cancer	0.00521	0.0097	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—uterine cancer	0.00491	0.00914	CbGbCtD
Imatinib—CYP3A4—Etoposide—uterine cancer	0.00458	0.00852	CbGbCtD
Imatinib—Ponatinib—FGFR2—uterine cancer	0.00434	1	CrCbGaD
Imatinib—CYP3A4—Doxorubicin—uterine cancer	0.00312	0.00581	CbGbCtD
Imatinib—CA6—exocrine gland—uterine cancer	0.00251	0.0209	CbGeAlD
Imatinib—ABCA3—myometrium—uterine cancer	0.00242	0.0201	CbGeAlD
Imatinib—NTRK1—decidua—uterine cancer	0.00227	0.0189	CbGeAlD
Imatinib—DDR1—myometrium—uterine cancer	0.00224	0.0186	CbGeAlD
Imatinib—ABCA3—decidua—uterine cancer	0.0018	0.0149	CbGeAlD
Imatinib—DDR1—uterine cervix—uterine cancer	0.00174	0.0145	CbGeAlD
Imatinib—ABCA3—endometrium—uterine cancer	0.00171	0.0142	CbGeAlD
Imatinib—DDR1—smooth muscle tissue—uterine cancer	0.00169	0.0141	CbGeAlD
Imatinib—DDR1—decidua—uterine cancer	0.00166	0.0138	CbGeAlD
Imatinib—ABCA3—mammalian vulva—uterine cancer	0.00165	0.0137	CbGeAlD
Imatinib—DDR1—endometrium—uterine cancer	0.00157	0.0131	CbGeAlD
Imatinib—DDR1—mammalian vulva—uterine cancer	0.00152	0.0127	CbGeAlD
Imatinib—KIT—exocrine gland—uterine cancer	0.00146	0.0121	CbGeAlD
Imatinib—DDR1—uterus—uterine cancer	0.00145	0.0121	CbGeAlD
Imatinib—HIPK4—female reproductive system—uterine cancer	0.00143	0.0119	CbGeAlD
Imatinib—PIP4K2C—myometrium—uterine cancer	0.00138	0.0115	CbGeAlD
Imatinib—CA3—myometrium—uterine cancer	0.00132	0.011	CbGeAlD
Imatinib—ABCA3—female gonad—uterine cancer	0.00129	0.0107	CbGeAlD
Imatinib—ABCA3—vagina—uterine cancer	0.00128	0.0106	CbGeAlD
Imatinib—DDR1—female gonad—uterine cancer	0.00119	0.00986	CbGeAlD
Imatinib—DDR1—vagina—uterine cancer	0.00118	0.0098	CbGeAlD
Imatinib—PTGS1—oviduct—uterine cancer	0.00116	0.00961	CbGeAlD
Imatinib—PIP4K2C—uterine cervix—uterine cancer	0.00107	0.00893	CbGeAlD
Imatinib—CA7—renal system—uterine cancer	0.00105	0.00869	CbGeAlD
Imatinib—CA3—uterine cervix—uterine cancer	0.00103	0.00852	CbGeAlD
Imatinib—PIP4K2C—decidua—uterine cancer	0.00102	0.00851	CbGeAlD
Imatinib—NQO2—myometrium—uterine cancer	0.00101	0.00843	CbGeAlD
Imatinib—PIP4K2C—endometrium—uterine cancer	0.000972	0.00807	CbGeAlD
Imatinib—LCK—uterine cervix—uterine cancer	0.000954	0.00792	CbGeAlD
Imatinib—PIP4K2C—mammalian vulva—uterine cancer	0.00094	0.00781	CbGeAlD
Imatinib—LCK—decidua—uterine cancer	0.000909	0.00755	CbGeAlD
Imatinib—CSF1R—myometrium—uterine cancer	0.000891	0.0074	CbGeAlD
Imatinib—CA2—exocrine gland—uterine cancer	0.000865	0.00719	CbGeAlD
Imatinib—CA3—uterus—uterine cancer	0.000855	0.0071	CbGeAlD
Imatinib—LCK—mammalian vulva—uterine cancer	0.000835	0.00693	CbGeAlD
Imatinib—ABCA3—lymph node—uterine cancer	0.000827	0.00687	CbGeAlD
Imatinib—SLC47A1—myometrium—uterine cancer	0.000814	0.00676	CbGeAlD
Imatinib—KIT—myometrium—uterine cancer	0.000809	0.00672	CbGeAlD
Imatinib—PIP4K2C—female reproductive system—uterine cancer	0.000805	0.00669	CbGeAlD
Imatinib—LCK—uterus—uterine cancer	0.000795	0.0066	CbGeAlD
Imatinib—PDGFRB—myometrium—uterine cancer	0.00079	0.00656	CbGeAlD
Imatinib—NQO2—uterine cervix—uterine cancer	0.000789	0.00656	CbGeAlD
Imatinib—ABL2—female gonad—uterine cancer	0.000774	0.00643	CbGeAlD
Imatinib—ABL2—vagina—uterine cancer	0.00077	0.00639	CbGeAlD
Imatinib—PTGS1—artery—uterine cancer	0.000767	0.00637	CbGeAlD
Imatinib—PDGFRA—smooth muscle tissue—uterine cancer	0.000765	0.00636	CbGeAlD
Imatinib—DDR1—lymph node—uterine cancer	0.000763	0.00634	CbGeAlD
Imatinib—NQO2—decidua—uterine cancer	0.000752	0.00625	CbGeAlD
Imatinib—PDGFRA—decidua—uterine cancer	0.00075	0.00623	CbGeAlD
Imatinib—NQO2—renal system—uterine cancer	0.000738	0.00613	CbGeAlD
Imatinib—PDGFRA—renal system—uterine cancer	0.000737	0.00612	CbGeAlD
Imatinib—CA9—female reproductive system—uterine cancer	0.000736	0.00611	CbGeAlD
Imatinib—PIP4K2C—female gonad—uterine cancer	0.000733	0.00609	CbGeAlD
Imatinib—PIP4K2C—vagina—uterine cancer	0.000728	0.00605	CbGeAlD
Imatinib—NQO2—endometrium—uterine cancer	0.000714	0.00593	CbGeAlD
Imatinib—ABL1—myometrium—uterine cancer	0.000704	0.00585	CbGeAlD
Imatinib—SLC22A2—renal system—uterine cancer	0.0007	0.00581	CbGeAlD
Imatinib—CA3—vagina—uterine cancer	0.000695	0.00578	CbGeAlD
Imatinib—CSF1R—uterine cervix—uterine cancer	0.000693	0.00576	CbGeAlD
Imatinib—NQO2—mammalian vulva—uterine cancer	0.000691	0.00574	CbGeAlD
Imatinib—CA12—renal system—uterine cancer	0.00068	0.00565	CbGeAlD
Imatinib—CSF1R—smooth muscle tissue—uterine cancer	0.000674	0.0056	CbGeAlD
Imatinib—CSF1R—decidua—uterine cancer	0.00066	0.00549	CbGeAlD
Imatinib—NQO2—uterus—uterine cancer	0.000658	0.00546	CbGeAlD
Imatinib—PDGFRA—uterus—uterine cancer	0.000656	0.00545	CbGeAlD
Imatinib—LCK—female gonad—uterine cancer	0.00065	0.0054	CbGeAlD
Imatinib—LCK—vagina—uterine cancer	0.000646	0.00537	CbGeAlD
Imatinib—KIT—epithelium—uterine cancer	0.000635	0.00527	CbGeAlD
Imatinib—SLC47A1—uterine cervix—uterine cancer	0.000633	0.00526	CbGeAlD
Imatinib—KIT—uterine cervix—uterine cancer	0.000629	0.00523	CbGeAlD
Imatinib—CSF1R—endometrium—uterine cancer	0.000627	0.00521	CbGeAlD
Imatinib—PDGFRB—epithelium—uterine cancer	0.00062	0.00515	CbGeAlD
Imatinib—PDGFRB—uterine cervix—uterine cancer	0.000615	0.00511	CbGeAlD
Imatinib—KIT—smooth muscle tissue—uterine cancer	0.000612	0.00508	CbGeAlD
Imatinib—CSF1R—mammalian vulva—uterine cancer	0.000606	0.00504	CbGeAlD
Imatinib—SLC47A1—decidua—uterine cancer	0.000603	0.00501	CbGeAlD
Imatinib—KIT—decidua—uterine cancer	0.0006	0.00498	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—uterine cancer	0.000597	0.00496	CbGeAlD
Imatinib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.000596	0.173	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.000596	0.173	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.000596	0.173	CbGdCrCtD
Imatinib—SLC47A1—renal system—uterine cancer	0.000592	0.00492	CbGeAlD
Imatinib—NQO2—female reproductive system—uterine cancer	0.000591	0.00491	CbGeAlD
Imatinib—PDGFRA—female reproductive system—uterine cancer	0.00059	0.0049	CbGeAlD
Imatinib—KIT—renal system—uterine cancer	0.000589	0.00489	CbGeAlD
Imatinib—PDGFRB—decidua—uterine cancer	0.000586	0.00487	CbGeAlD
Imatinib—CSF1R—uterus—uterine cancer	0.000578	0.0048	CbGeAlD
Imatinib—PDGFRB—renal system—uterine cancer	0.000575	0.00478	CbGeAlD
Imatinib—SLC47A1—endometrium—uterine cancer	0.000573	0.00476	CbGeAlD
Imatinib—KIT—endometrium—uterine cancer	0.000569	0.00473	CbGeAlD
Imatinib—PDGFRB—endometrium—uterine cancer	0.000556	0.00462	CbGeAlD
Imatinib—SLC47A1—mammalian vulva—uterine cancer	0.000554	0.0046	CbGeAlD
Imatinib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000552	0.16	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000552	0.16	CbGdCrCtD
Imatinib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000552	0.16	CbGdCrCtD
Imatinib—KIT—mammalian vulva—uterine cancer	0.000551	0.00457	CbGeAlD
Imatinib—ABL1—uterine cervix—uterine cancer	0.000548	0.00455	CbGeAlD
Imatinib—CA12—female reproductive system—uterine cancer	0.000544	0.00452	CbGeAlD
Imatinib—CA1—renal system—uterine cancer	0.000539	0.00447	CbGeAlD
Imatinib—NQO2—female gonad—uterine cancer	0.000538	0.00447	CbGeAlD
Imatinib—PDGFRB—mammalian vulva—uterine cancer	0.000538	0.00447	CbGeAlD
Imatinib—PDGFRA—female gonad—uterine cancer	0.000537	0.00446	CbGeAlD
Imatinib—NQO2—vagina—uterine cancer	0.000535	0.00444	CbGeAlD
Imatinib—PDGFRA—vagina—uterine cancer	0.000534	0.00443	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—uterine cancer	0.000533	0.00442	CbGeAlD
Imatinib—SLC47A1—uterus—uterine cancer	0.000528	0.00438	CbGeAlD
Imatinib—KIT—uterus—uterine cancer	0.000525	0.00436	CbGeAlD
Imatinib—ABL1—decidua—uterine cancer	0.000522	0.00434	CbGeAlD
Imatinib—ORM1—endometrium—uterine cancer	0.000522	0.00433	CbGeAlD
Imatinib—CSF1R—female reproductive system—uterine cancer	0.000519	0.00431	CbGeAlD
Imatinib—ABL1—renal system—uterine cancer	0.000513	0.00426	CbGeAlD
Imatinib—PDGFRB—uterus—uterine cancer	0.000512	0.00426	CbGeAlD
Imatinib—ABL2—lymph node—uterine cancer	0.000498	0.00414	CbGeAlD
Imatinib—ABL1—endometrium—uterine cancer	0.000496	0.00412	CbGeAlD
Imatinib—SLC22A1—renal system—uterine cancer	0.000494	0.0041	CbGeAlD
Imatinib—ABL1—mammalian vulva—uterine cancer	0.000479	0.00398	CbGeAlD
Imatinib—SLC47A1—female reproductive system—uterine cancer	0.000474	0.00394	CbGeAlD
Imatinib—CSF1R—female gonad—uterine cancer	0.000473	0.00393	CbGeAlD
Imatinib—KIT—female reproductive system—uterine cancer	0.000472	0.00392	CbGeAlD
Imatinib—PIP4K2C—lymph node—uterine cancer	0.000471	0.00391	CbGeAlD
Imatinib—CSF1R—vagina—uterine cancer	0.00047	0.0039	CbGeAlD
Imatinib—PDGFRB—female reproductive system—uterine cancer	0.000461	0.00383	CbGeAlD
Imatinib—ABL1—uterus—uterine cancer	0.000457	0.00379	CbGeAlD
Imatinib—CA3—lymph node—uterine cancer	0.00045	0.00374	CbGeAlD
Imatinib—ABCG2—myometrium—uterine cancer	0.000444	0.00369	CbGeAlD
Imatinib—ORM1—female reproductive system—uterine cancer	0.000432	0.00359	CbGeAlD
Imatinib—SLC47A1—female gonad—uterine cancer	0.000432	0.00359	CbGeAlD
Imatinib—CA1—female reproductive system—uterine cancer	0.000431	0.00358	CbGeAlD
Imatinib—KIT—female gonad—uterine cancer	0.000429	0.00356	CbGeAlD
Imatinib—SLC47A1—vagina—uterine cancer	0.000429	0.00356	CbGeAlD
Imatinib—KIT—vagina—uterine cancer	0.000427	0.00354	CbGeAlD
Imatinib—PDGFRB—female gonad—uterine cancer	0.000419	0.00348	CbGeAlD
Imatinib—LCK—lymph node—uterine cancer	0.000418	0.00347	CbGeAlD
Imatinib—PDGFRB—vagina—uterine cancer	0.000417	0.00346	CbGeAlD
Imatinib—ABL1—female reproductive system—uterine cancer	0.000411	0.00341	CbGeAlD
Imatinib—CA2—epithelium—uterine cancer	0.000376	0.00313	CbGeAlD
Imatinib—ABL1—female gonad—uterine cancer	0.000374	0.0031	CbGeAlD
Imatinib—ABL1—vagina—uterine cancer	0.000371	0.00308	CbGeAlD
Imatinib—CA2—smooth muscle tissue—uterine cancer	0.000363	0.00301	CbGeAlD
Imatinib—SLC22A1—vagina—uterine cancer	0.000358	0.00297	CbGeAlD
Imatinib—CA2—decidua—uterine cancer	0.000355	0.00295	CbGeAlD
Imatinib—CA2—renal system—uterine cancer	0.000349	0.0029	CbGeAlD
Imatinib—NQO2—lymph node—uterine cancer	0.000346	0.00287	CbGeAlD
Imatinib—ABCG2—uterine cervix—uterine cancer	0.000346	0.00287	CbGeAlD
Imatinib—PDGFRA—lymph node—uterine cancer	0.000345	0.00287	CbGeAlD
Imatinib—ABCG2—decidua—uterine cancer	0.000329	0.00273	CbGeAlD
Imatinib—CA2—mammalian vulva—uterine cancer	0.000326	0.00271	CbGeAlD
Imatinib—CYP3A5—uterine cervix—uterine cancer	0.000321	0.00266	CbGeAlD
Imatinib—ABCG2—endometrium—uterine cancer	0.000313	0.0026	CbGeAlD
Imatinib—CYP1A2—renal system—uterine cancer	0.000311	0.00258	CbGeAlD
Imatinib—CSF1R—lymph node—uterine cancer	0.000304	0.00252	CbGeAlD
Imatinib—ABCG2—mammalian vulva—uterine cancer	0.000302	0.00251	CbGeAlD
Imatinib—CYP3A5—renal system—uterine cancer	0.0003	0.00249	CbGeAlD
Imatinib—PTGS1—epithelium—uterine cancer	0.000291	0.00241	CbGeAlD
Imatinib—PTGS1—uterine cervix—uterine cancer	0.000288	0.00239	CbGeAlD
Imatinib—ABCG2—uterus—uterine cancer	0.000288	0.00239	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—uterine cancer	0.00028	0.00233	CbGeAlD
Imatinib—CA2—female reproductive system—uterine cancer	0.00028	0.00232	CbGeAlD
Imatinib—SLC47A1—lymph node—uterine cancer	0.000277	0.0023	CbGeAlD
Imatinib—CYP2C19—vagina—uterine cancer	0.000276	0.00229	CbGeAlD
Imatinib—KIT—lymph node—uterine cancer	0.000276	0.00229	CbGeAlD
Imatinib—PTGS1—renal system—uterine cancer	0.00027	0.00224	CbGeAlD
Imatinib—PDGFRB—lymph node—uterine cancer	0.000269	0.00224	CbGeAlD
Imatinib—PTGS1—endometrium—uterine cancer	0.000261	0.00217	CbGeAlD
Imatinib—CA2—female gonad—uterine cancer	0.000254	0.00211	CbGeAlD
Imatinib—CA2—vagina—uterine cancer	0.000253	0.0021	CbGeAlD
Imatinib—ORM1—lymph node—uterine cancer	0.000253	0.0021	CbGeAlD
Imatinib—CA1—lymph node—uterine cancer	0.000252	0.0021	CbGeAlD
Imatinib—PTGS1—mammalian vulva—uterine cancer	0.000252	0.00209	CbGeAlD
Imatinib—PTGS1—uterus—uterine cancer	0.00024	0.002	CbGeAlD
Imatinib—ABL1—lymph node—uterine cancer	0.00024	0.00199	CbGeAlD
Imatinib—CYP2C9—female reproductive system—uterine cancer	0.000237	0.00196	CbGeAlD
Imatinib—ABCG2—female gonad—uterine cancer	0.000236	0.00196	CbGeAlD
Imatinib—ABCG2—vagina—uterine cancer	0.000234	0.00194	CbGeAlD
Imatinib—CYP3A4—renal system—uterine cancer	0.000225	0.00187	CbGeAlD
Imatinib—ALB—lymph node—uterine cancer	0.000222	0.00184	CbGeAlD
Imatinib—CYP2D6—renal system—uterine cancer	0.000222	0.00184	CbGeAlD
Imatinib—ABCB1—myometrium—uterine cancer	0.000219	0.00182	CbGeAlD
Imatinib—CYP3A5—female gonad—uterine cancer	0.000219	0.00182	CbGeAlD
Imatinib—CYP3A5—vagina—uterine cancer	0.000217	0.00181	CbGeAlD
Imatinib—PTGS1—female reproductive system—uterine cancer	0.000216	0.00179	CbGeAlD
Imatinib—PTGS1—female gonad—uterine cancer	0.000196	0.00163	CbGeAlD
Imatinib—PTGS1—vagina—uterine cancer	0.000195	0.00162	CbGeAlD
Imatinib—CYP3A4—female reproductive system—uterine cancer	0.00018	0.0015	CbGeAlD
Imatinib—CYP2D6—female reproductive system—uterine cancer	0.000177	0.00147	CbGeAlD
Imatinib—ABCB1—epithelium—uterine cancer	0.000172	0.00143	CbGeAlD
Imatinib—ABCB1—uterine cervix—uterine cancer	0.00017	0.00142	CbGeAlD
Imatinib—CA2—lymph node—uterine cancer	0.000164	0.00136	CbGeAlD
Imatinib—ABCB1—decidua—uterine cancer	0.000162	0.00135	CbGeAlD
Imatinib—CYP2D6—female gonad—uterine cancer	0.000161	0.00134	CbGeAlD
Imatinib—ABCB1—renal system—uterine cancer	0.000159	0.00132	CbGeAlD
Imatinib—ABCB1—endometrium—uterine cancer	0.000154	0.00128	CbGeAlD
Imatinib—ABCG2—lymph node—uterine cancer	0.000151	0.00126	CbGeAlD
Imatinib—ABCB1—mammalian vulva—uterine cancer	0.000149	0.00124	CbGeAlD
Imatinib—ABCB1—uterus—uterine cancer	0.000142	0.00118	CbGeAlD
Imatinib—ABCB1—female reproductive system—uterine cancer	0.000128	0.00106	CbGeAlD
Imatinib—PTGS1—lymph node—uterine cancer	0.000126	0.00105	CbGeAlD
Imatinib—ABCB1—female gonad—uterine cancer	0.000116	0.000965	CbGeAlD
Imatinib—ABCB1—vagina—uterine cancer	0.000115	0.000959	CbGeAlD
Imatinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000103	0.000487	CcSEcCtD
Imatinib—Neutropenia—Epirubicin—uterine cancer	0.000102	0.000482	CcSEcCtD
Imatinib—Abdominal distension—Doxorubicin—uterine cancer	0.000102	0.00048	CcSEcCtD
Imatinib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000101	0.000479	CcSEcCtD
Imatinib—Influenza—Doxorubicin—uterine cancer	0.000101	0.000477	CcSEcCtD
Imatinib—Dysphagia—Doxorubicin—uterine cancer	0.000101	0.000477	CcSEcCtD
Imatinib—Pollakiuria—Epirubicin—uterine cancer	0.000101	0.000476	CcSEcCtD
Imatinib—Eosinophilia—Doxorubicin—uterine cancer	0.0001	0.000472	CcSEcCtD
Imatinib—Photosensitivity reaction—Epirubicin—uterine cancer	9.96e-05	0.000471	CcSEcCtD
Imatinib—Paraesthesia—Etoposide—uterine cancer	9.94e-05	0.00047	CcSEcCtD
Imatinib—Weight increased—Epirubicin—uterine cancer	9.93e-05	0.000469	CcSEcCtD
Imatinib—Pancreatitis—Doxorubicin—uterine cancer	9.9e-05	0.000468	CcSEcCtD
Imatinib—Weight decreased—Epirubicin—uterine cancer	9.87e-05	0.000467	CcSEcCtD
Imatinib—Dyspnoea—Etoposide—uterine cancer	9.87e-05	0.000466	CcSEcCtD
Imatinib—Hyperglycaemia—Epirubicin—uterine cancer	9.85e-05	0.000465	CcSEcCtD
Imatinib—Somnolence—Etoposide—uterine cancer	9.84e-05	0.000465	CcSEcCtD
Imatinib—Angina pectoris—Doxorubicin—uterine cancer	9.84e-05	0.000465	CcSEcCtD
Imatinib—Pneumonia—Epirubicin—uterine cancer	9.79e-05	0.000462	CcSEcCtD
Imatinib—Infestation NOS—Epirubicin—uterine cancer	9.73e-05	0.00046	CcSEcCtD
Imatinib—Infestation—Epirubicin—uterine cancer	9.73e-05	0.00046	CcSEcCtD
Imatinib—Vomiting—Dactinomycin—uterine cancer	9.73e-05	0.00046	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	9.65e-05	0.000456	CcSEcCtD
Imatinib—Rash—Dactinomycin—uterine cancer	9.65e-05	0.000456	CcSEcCtD
Imatinib—Decreased appetite—Etoposide—uterine cancer	9.63e-05	0.000455	CcSEcCtD
Imatinib—Pancytopenia—Doxorubicin—uterine cancer	9.59e-05	0.000453	CcSEcCtD
Imatinib—Renal failure—Epirubicin—uterine cancer	9.57e-05	0.000452	CcSEcCtD
Imatinib—Gastrointestinal disorder—Etoposide—uterine cancer	9.56e-05	0.000452	CcSEcCtD
Imatinib—Fatigue—Etoposide—uterine cancer	9.55e-05	0.000451	CcSEcCtD
Imatinib—Neuropathy peripheral—Epirubicin—uterine cancer	9.54e-05	0.000451	CcSEcCtD
Imatinib—Stomatitis—Epirubicin—uterine cancer	9.49e-05	0.000448	CcSEcCtD
Imatinib—Jaundice—Epirubicin—uterine cancer	9.49e-05	0.000448	CcSEcCtD
Imatinib—Pain—Etoposide—uterine cancer	9.47e-05	0.000447	CcSEcCtD
Imatinib—Constipation—Etoposide—uterine cancer	9.47e-05	0.000447	CcSEcCtD
Imatinib—Conjunctivitis—Epirubicin—uterine cancer	9.46e-05	0.000447	CcSEcCtD
Imatinib—Urinary tract infection—Epirubicin—uterine cancer	9.46e-05	0.000447	CcSEcCtD
Imatinib—Neutropenia—Doxorubicin—uterine cancer	9.44e-05	0.000446	CcSEcCtD
Imatinib—Upper respiratory tract infection—Doxorubicin—uterine cancer	9.39e-05	0.000443	CcSEcCtD
Imatinib—Sweating—Epirubicin—uterine cancer	9.33e-05	0.000441	CcSEcCtD
Imatinib—Pollakiuria—Doxorubicin—uterine cancer	9.33e-05	0.000441	CcSEcCtD
Imatinib—Haematuria—Epirubicin—uterine cancer	9.28e-05	0.000438	CcSEcCtD
Imatinib—Photosensitivity reaction—Doxorubicin—uterine cancer	9.22e-05	0.000436	CcSEcCtD
Imatinib—Hepatobiliary disease—Epirubicin—uterine cancer	9.2e-05	0.000435	CcSEcCtD
Imatinib—Weight increased—Doxorubicin—uterine cancer	9.19e-05	0.000434	CcSEcCtD
Imatinib—Epistaxis—Epirubicin—uterine cancer	9.18e-05	0.000434	CcSEcCtD
Imatinib—Weight decreased—Doxorubicin—uterine cancer	9.14e-05	0.000432	CcSEcCtD
Imatinib—Sinusitis—Epirubicin—uterine cancer	9.13e-05	0.000431	CcSEcCtD
Imatinib—Feeling abnormal—Etoposide—uterine cancer	9.12e-05	0.000431	CcSEcCtD
Imatinib—Hyperglycaemia—Doxorubicin—uterine cancer	9.11e-05	0.00043	CcSEcCtD
Imatinib—Nausea—Dactinomycin—uterine cancer	9.09e-05	0.000429	CcSEcCtD
Imatinib—Agranulocytosis—Epirubicin—uterine cancer	9.08e-05	0.000429	CcSEcCtD
Imatinib—Pneumonia—Doxorubicin—uterine cancer	9.06e-05	0.000428	CcSEcCtD
Imatinib—Gastrointestinal pain—Etoposide—uterine cancer	9.05e-05	0.000428	CcSEcCtD
Imatinib—Infestation NOS—Doxorubicin—uterine cancer	9e-05	0.000425	CcSEcCtD
Imatinib—Infestation—Doxorubicin—uterine cancer	9e-05	0.000425	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	8.93e-05	0.000422	CcSEcCtD
Imatinib—Renal failure—Doxorubicin—uterine cancer	8.85e-05	0.000418	CcSEcCtD
Imatinib—Neuropathy peripheral—Doxorubicin—uterine cancer	8.83e-05	0.000417	CcSEcCtD
Imatinib—Urticaria—Etoposide—uterine cancer	8.8e-05	0.000416	CcSEcCtD
Imatinib—Haemoglobin—Epirubicin—uterine cancer	8.78e-05	0.000415	CcSEcCtD
Imatinib—Stomatitis—Doxorubicin—uterine cancer	8.78e-05	0.000415	CcSEcCtD
Imatinib—Jaundice—Doxorubicin—uterine cancer	8.78e-05	0.000415	CcSEcCtD
Imatinib—Rhinitis—Epirubicin—uterine cancer	8.76e-05	0.000414	CcSEcCtD
Imatinib—Abdominal pain—Etoposide—uterine cancer	8.75e-05	0.000414	CcSEcCtD
Imatinib—Body temperature increased—Etoposide—uterine cancer	8.75e-05	0.000414	CcSEcCtD
Imatinib—Conjunctivitis—Doxorubicin—uterine cancer	8.75e-05	0.000414	CcSEcCtD
Imatinib—Urinary tract infection—Doxorubicin—uterine cancer	8.75e-05	0.000414	CcSEcCtD
Imatinib—Haemorrhage—Epirubicin—uterine cancer	8.74e-05	0.000413	CcSEcCtD
Imatinib—Hepatitis—Epirubicin—uterine cancer	8.74e-05	0.000413	CcSEcCtD
Imatinib—Hypoaesthesia—Epirubicin—uterine cancer	8.69e-05	0.000411	CcSEcCtD
Imatinib—Pharyngitis—Epirubicin—uterine cancer	8.67e-05	0.00041	CcSEcCtD
Imatinib—Sweating—Doxorubicin—uterine cancer	8.63e-05	0.000408	CcSEcCtD
Imatinib—Urinary tract disorder—Epirubicin—uterine cancer	8.63e-05	0.000408	CcSEcCtD
Imatinib—Oedema peripheral—Epirubicin—uterine cancer	8.61e-05	0.000407	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—uterine cancer	8.59e-05	0.000406	CcSEcCtD
Imatinib—Connective tissue disorder—Epirubicin—uterine cancer	8.58e-05	0.000406	CcSEcCtD
Imatinib—Urethral disorder—Epirubicin—uterine cancer	8.56e-05	0.000405	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—uterine cancer	8.52e-05	0.000402	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—uterine cancer	8.49e-05	0.000401	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—uterine cancer	8.45e-05	0.000399	CcSEcCtD
Imatinib—Agranulocytosis—Doxorubicin—uterine cancer	8.4e-05	0.000397	CcSEcCtD
Imatinib—Erythema multiforme—Epirubicin—uterine cancer	8.26e-05	0.00039	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—uterine cancer	8.16e-05	0.000386	CcSEcCtD
Imatinib—Hypersensitivity—Etoposide—uterine cancer	8.16e-05	0.000385	CcSEcCtD
Imatinib—Tinnitus—Epirubicin—uterine cancer	8.15e-05	0.000385	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—uterine cancer	8.12e-05	0.000384	CcSEcCtD
Imatinib—Flushing—Epirubicin—uterine cancer	8.11e-05	0.000383	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—uterine cancer	8.11e-05	0.000383	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—uterine cancer	8.1e-05	0.000383	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—uterine cancer	8.08e-05	0.000382	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—uterine cancer	8.08e-05	0.000382	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—uterine cancer	8.04e-05	0.00038	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—uterine cancer	8.02e-05	0.000379	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—uterine cancer	7.98e-05	0.000377	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—uterine cancer	7.96e-05	0.000376	CcSEcCtD
Imatinib—Asthenia—Etoposide—uterine cancer	7.94e-05	0.000375	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—uterine cancer	7.94e-05	0.000375	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—uterine cancer	7.93e-05	0.000374	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—uterine cancer	7.92e-05	0.000374	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—uterine cancer	7.89e-05	0.000373	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—uterine cancer	7.87e-05	0.000372	CcSEcCtD
Imatinib—Chills—Epirubicin—uterine cancer	7.84e-05	0.00037	CcSEcCtD
Imatinib—Pruritus—Etoposide—uterine cancer	7.83e-05	0.00037	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—uterine cancer	7.8e-05	0.000369	CcSEcCtD
Imatinib—Alopecia—Epirubicin—uterine cancer	7.72e-05	0.000365	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—uterine cancer	7.65e-05	0.000362	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—uterine cancer	7.64e-05	0.000361	CcSEcCtD
Imatinib—Erythema—Epirubicin—uterine cancer	7.61e-05	0.000359	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—uterine cancer	7.61e-05	0.000359	CcSEcCtD
Imatinib—Diarrhoea—Etoposide—uterine cancer	7.58e-05	0.000358	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—uterine cancer	7.55e-05	0.000357	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—uterine cancer	7.54e-05	0.000356	CcSEcCtD
Imatinib—Flushing—Doxorubicin—uterine cancer	7.5e-05	0.000354	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—uterine cancer	7.5e-05	0.000354	CcSEcCtD
Imatinib—Flatulence—Epirubicin—uterine cancer	7.49e-05	0.000354	CcSEcCtD
Imatinib—ABCB1—lymph node—uterine cancer	7.47e-05	0.00062	CbGeAlD
Imatinib—Dysgeusia—Epirubicin—uterine cancer	7.45e-05	0.000352	CcSEcCtD
Imatinib—Back pain—Epirubicin—uterine cancer	7.36e-05	0.000348	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—uterine cancer	7.33e-05	0.000347	CcSEcCtD
Imatinib—Dizziness—Etoposide—uterine cancer	7.32e-05	0.000346	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—uterine cancer	7.31e-05	0.000345	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—uterine cancer	7.3e-05	0.000345	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—uterine cancer	7.29e-05	0.000344	CcSEcCtD
Imatinib—Chills—Doxorubicin—uterine cancer	7.25e-05	0.000343	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—uterine cancer	7.22e-05	0.000341	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—uterine cancer	7.17e-05	0.000339	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—uterine cancer	7.14e-05	0.000337	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—uterine cancer	7.08e-05	0.000335	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—uterine cancer	7.06e-05	0.000333	CcSEcCtD
Imatinib—Vomiting—Etoposide—uterine cancer	7.04e-05	0.000333	CcSEcCtD
Imatinib—Erythema—Doxorubicin—uterine cancer	7.04e-05	0.000332	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—uterine cancer	7.04e-05	0.000332	CcSEcCtD
Imatinib—Anaemia—Epirubicin—uterine cancer	7.03e-05	0.000332	CcSEcCtD
Imatinib—Rash—Etoposide—uterine cancer	6.98e-05	0.00033	CcSEcCtD
Imatinib—Dermatitis—Etoposide—uterine cancer	6.98e-05	0.00033	CcSEcCtD
Imatinib—Headache—Etoposide—uterine cancer	6.94e-05	0.000328	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—uterine cancer	6.93e-05	0.000328	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—uterine cancer	6.89e-05	0.000326	CcSEcCtD
Imatinib—Malaise—Epirubicin—uterine cancer	6.86e-05	0.000324	CcSEcCtD
Imatinib—Vertigo—Epirubicin—uterine cancer	6.83e-05	0.000323	CcSEcCtD
Imatinib—Syncope—Epirubicin—uterine cancer	6.82e-05	0.000322	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—uterine cancer	6.81e-05	0.000322	CcSEcCtD
Imatinib—Back pain—Doxorubicin—uterine cancer	6.81e-05	0.000322	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—uterine cancer	6.77e-05	0.00032	CcSEcCtD
Imatinib—Palpitations—Epirubicin—uterine cancer	6.72e-05	0.000318	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—uterine cancer	6.68e-05	0.000316	CcSEcCtD
Imatinib—Cough—Epirubicin—uterine cancer	6.64e-05	0.000314	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—uterine cancer	6.63e-05	0.000313	CcSEcCtD
Imatinib—Convulsion—Epirubicin—uterine cancer	6.59e-05	0.000311	CcSEcCtD
Imatinib—Nausea—Etoposide—uterine cancer	6.58e-05	0.000311	CcSEcCtD
Imatinib—Hypertension—Epirubicin—uterine cancer	6.57e-05	0.00031	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—uterine cancer	6.53e-05	0.000308	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—uterine cancer	6.5e-05	0.000307	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—uterine cancer	6.47e-05	0.000306	CcSEcCtD
Imatinib—Chest pain—Epirubicin—uterine cancer	6.47e-05	0.000306	CcSEcCtD
Imatinib—Myalgia—Epirubicin—uterine cancer	6.47e-05	0.000306	CcSEcCtD
Imatinib—Anxiety—Epirubicin—uterine cancer	6.45e-05	0.000305	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.43e-05	0.000304	CcSEcCtD
Imatinib—Discomfort—Epirubicin—uterine cancer	6.4e-05	0.000302	CcSEcCtD
Imatinib—Malaise—Doxorubicin—uterine cancer	6.35e-05	0.0003	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—uterine cancer	6.33e-05	0.000299	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—uterine cancer	6.32e-05	0.000299	CcSEcCtD
Imatinib—Syncope—Doxorubicin—uterine cancer	6.31e-05	0.000298	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—uterine cancer	6.3e-05	0.000298	CcSEcCtD
Imatinib—Confusional state—Epirubicin—uterine cancer	6.26e-05	0.000296	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—uterine cancer	6.22e-05	0.000294	CcSEcCtD
Imatinib—Oedema—Epirubicin—uterine cancer	6.21e-05	0.000293	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—uterine cancer	6.21e-05	0.000293	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—uterine cancer	6.18e-05	0.000292	CcSEcCtD
Imatinib—Infection—Epirubicin—uterine cancer	6.17e-05	0.000291	CcSEcCtD
Imatinib—Cough—Doxorubicin—uterine cancer	6.14e-05	0.00029	CcSEcCtD
Imatinib—Shock—Epirubicin—uterine cancer	6.11e-05	0.000289	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—uterine cancer	6.1e-05	0.000288	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—uterine cancer	6.09e-05	0.000288	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—uterine cancer	6.08e-05	0.000287	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—uterine cancer	6.08e-05	0.000287	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—uterine cancer	6.06e-05	0.000286	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—uterine cancer	6.03e-05	0.000285	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—uterine cancer	6e-05	0.000283	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—uterine cancer	5.99e-05	0.000283	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—uterine cancer	5.99e-05	0.000283	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—uterine cancer	5.99e-05	0.000283	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—uterine cancer	5.97e-05	0.000282	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	5.95e-05	0.000281	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—uterine cancer	5.92e-05	0.00028	CcSEcCtD
Imatinib—Anorexia—Epirubicin—uterine cancer	5.92e-05	0.00028	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—uterine cancer	5.86e-05	0.000277	CcSEcCtD
Imatinib—Hypotension—Epirubicin—uterine cancer	5.8e-05	0.000274	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—uterine cancer	5.79e-05	0.000274	CcSEcCtD
Imatinib—Oedema—Doxorubicin—uterine cancer	5.74e-05	0.000271	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—uterine cancer	5.74e-05	0.000271	CcSEcCtD
Imatinib—Infection—Doxorubicin—uterine cancer	5.71e-05	0.00027	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.65e-05	0.000267	CcSEcCtD
Imatinib—Shock—Doxorubicin—uterine cancer	5.65e-05	0.000267	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—uterine cancer	5.63e-05	0.000266	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—uterine cancer	5.62e-05	0.000266	CcSEcCtD
Imatinib—Insomnia—Epirubicin—uterine cancer	5.61e-05	0.000265	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—uterine cancer	5.6e-05	0.000265	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—uterine cancer	5.58e-05	0.000264	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—uterine cancer	5.57e-05	0.000263	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—uterine cancer	5.55e-05	0.000262	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—uterine cancer	5.53e-05	0.000261	CcSEcCtD
Imatinib—Somnolence—Epirubicin—uterine cancer	5.52e-05	0.000261	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—uterine cancer	5.47e-05	0.000259	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—uterine cancer	5.46e-05	0.000258	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—uterine cancer	5.4e-05	0.000255	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—uterine cancer	5.37e-05	0.000254	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—uterine cancer	5.36e-05	0.000253	CcSEcCtD
Imatinib—Fatigue—Epirubicin—uterine cancer	5.35e-05	0.000253	CcSEcCtD
Imatinib—Constipation—Epirubicin—uterine cancer	5.31e-05	0.000251	CcSEcCtD
Imatinib—Pain—Epirubicin—uterine cancer	5.31e-05	0.000251	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.23e-05	0.000247	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—uterine cancer	5.19e-05	0.000245	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—uterine cancer	5.16e-05	0.000244	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—uterine cancer	5.12e-05	0.000242	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—uterine cancer	5.11e-05	0.000242	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—uterine cancer	5.11e-05	0.000241	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—uterine cancer	5.08e-05	0.00024	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—uterine cancer	5.06e-05	0.000239	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—uterine cancer	4.99e-05	0.000236	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	4.96e-05	0.000234	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—uterine cancer	4.95e-05	0.000234	CcSEcCtD
Imatinib—Urticaria—Epirubicin—uterine cancer	4.93e-05	0.000233	CcSEcCtD
Imatinib—Constipation—Doxorubicin—uterine cancer	4.91e-05	0.000232	CcSEcCtD
Imatinib—Pain—Doxorubicin—uterine cancer	4.91e-05	0.000232	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—uterine cancer	4.91e-05	0.000232	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—uterine cancer	4.91e-05	0.000232	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—uterine cancer	4.73e-05	0.000224	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—uterine cancer	4.7e-05	0.000222	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—uterine cancer	4.57e-05	0.000216	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—uterine cancer	4.56e-05	0.000216	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—uterine cancer	4.54e-05	0.000214	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—uterine cancer	4.54e-05	0.000214	CcSEcCtD
Imatinib—Asthenia—Epirubicin—uterine cancer	4.45e-05	0.00021	CcSEcCtD
Imatinib—Pruritus—Epirubicin—uterine cancer	4.39e-05	0.000207	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—uterine cancer	4.25e-05	0.000201	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—uterine cancer	4.23e-05	0.0002	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—uterine cancer	4.12e-05	0.000195	CcSEcCtD
Imatinib—Dizziness—Epirubicin—uterine cancer	4.1e-05	0.000194	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—uterine cancer	4.06e-05	0.000192	CcSEcCtD
Imatinib—Vomiting—Epirubicin—uterine cancer	3.95e-05	0.000186	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—uterine cancer	3.93e-05	0.000186	CcSEcCtD
Imatinib—Rash—Epirubicin—uterine cancer	3.91e-05	0.000185	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—uterine cancer	3.91e-05	0.000185	CcSEcCtD
Imatinib—Headache—Epirubicin—uterine cancer	3.89e-05	0.000184	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—uterine cancer	3.8e-05	0.000179	CcSEcCtD
Imatinib—Nausea—Epirubicin—uterine cancer	3.69e-05	0.000174	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—uterine cancer	3.65e-05	0.000173	CcSEcCtD
Imatinib—Rash—Doxorubicin—uterine cancer	3.62e-05	0.000171	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—uterine cancer	3.62e-05	0.000171	CcSEcCtD
Imatinib—Headache—Doxorubicin—uterine cancer	3.6e-05	0.00017	CcSEcCtD
Imatinib—Nausea—Doxorubicin—uterine cancer	3.41e-05	0.000161	CcSEcCtD
Imatinib—CYP2D6—Metabolism—CYP11A1—uterine cancer	7.55e-06	6.14e-05	CbGpPWpGaD
Imatinib—CA2—Metabolism—PIK3CA—uterine cancer	7.55e-06	6.14e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—NRAS—uterine cancer	7.51e-06	6.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—AKT1—uterine cancer	7.5e-06	6.1e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP11A1—uterine cancer	7.48e-06	6.08e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EP300—uterine cancer	7.48e-06	6.08e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EP300—uterine cancer	7.41e-06	6.02e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PTEN—uterine cancer	7.39e-06	6.01e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—PIK3CA—uterine cancer	7.37e-06	5.99e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FGFR2—uterine cancer	7.34e-06	5.97e-05	CbGpPWpGaD
Imatinib—KIT—Disease—NRAS—uterine cancer	7.32e-06	5.95e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—AKT1—uterine cancer	7.31e-06	5.94e-05	CbGpPWpGaD
Imatinib—CA1—Metabolism—PIK3CA—uterine cancer	7.23e-06	5.88e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EP300—uterine cancer	7.23e-06	5.88e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—AKT1—uterine cancer	7.2e-06	5.86e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CTNNB1—uterine cancer	7.18e-06	5.84e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—ERBB2—uterine cancer	7.13e-06	5.8e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKR1C3—uterine cancer	7.13e-06	5.8e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—uterine cancer	7.08e-06	5.76e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—PIK3CA—uterine cancer	7.07e-06	5.75e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKR1C3—uterine cancer	7.07e-06	5.75e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EP300—uterine cancer	7.04e-06	5.73e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PTEN—uterine cancer	7e-06	5.69e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NRAS—uterine cancer	7e-06	5.69e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—RRM2—uterine cancer	6.99e-06	5.69e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.93e-06	5.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NRAS—uterine cancer	6.93e-06	5.64e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCL2—uterine cancer	6.89e-06	5.61e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—KRAS—uterine cancer	6.82e-06	5.55e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HRAS—uterine cancer	6.82e-06	5.54e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—DCN—uterine cancer	6.79e-06	5.52e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—NRAS—uterine cancer	6.76e-06	5.5e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ERBB2—uterine cancer	6.74e-06	5.48e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—STK11—uterine cancer	6.73e-06	5.47e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP19A1—uterine cancer	6.73e-06	5.47e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—AKT1—uterine cancer	6.69e-06	5.44e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EP300—uterine cancer	6.67e-06	5.43e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—EP300—uterine cancer	6.61e-06	5.38e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CDKN1B—uterine cancer	6.61e-06	5.37e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—NRAS—uterine cancer	6.59e-06	5.36e-05	CbGpPWpGaD
Imatinib—LCK—Disease—ERBB2—uterine cancer	6.59e-06	5.36e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HRAS—uterine cancer	6.55e-06	5.32e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—POLD1—uterine cancer	6.47e-06	5.26e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KRAS—uterine cancer	6.46e-06	5.25e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP11A1—uterine cancer	6.39e-06	5.2e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL8—uterine cancer	6.39e-06	5.2e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB2—uterine cancer	6.38e-06	5.19e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—PIK3CA—uterine cancer	6.36e-06	5.17e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.31e-06	5.13e-05	CbGpPWpGaD
Imatinib—KIT—Disease—KRAS—uterine cancer	6.3e-06	5.12e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ESR1—uterine cancer	6.28e-06	5.11e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—PIK3CA—uterine cancer	6.27e-06	5.1e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—uterine cancer	6.26e-06	5.09e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NRAS—uterine cancer	6.24e-06	5.08e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CDKN1B—uterine cancer	6.24e-06	5.08e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CTNNB1—uterine cancer	6.24e-06	5.08e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NRAS—uterine cancer	6.19e-06	5.03e-05	CbGpPWpGaD
Imatinib—CA2—Metabolism—AKT1—uterine cancer	6.16e-06	5.01e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CDKN1B—uterine cancer	6.1e-06	4.96e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PTEN—uterine cancer	6.08e-06	4.95e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKR1C1—uterine cancer	6.05e-06	4.92e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL8—uterine cancer	6.05e-06	4.92e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKR1C3—uterine cancer	6.04e-06	4.91e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP19A1—uterine cancer	6.04e-06	4.91e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—STK11—uterine cancer	6.04e-06	4.91e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KRAS—uterine cancer	6.02e-06	4.9e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.02e-06	4.9e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—AKT1—uterine cancer	6.02e-06	4.89e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KRAS—uterine cancer	5.96e-06	4.85e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—PIK3CA—uterine cancer	5.94e-06	4.83e-05	CbGpPWpGaD
Imatinib—CA1—Metabolism—AKT1—uterine cancer	5.91e-06	4.81e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN1B—uterine cancer	5.91e-06	4.8e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CTNNB1—uterine cancer	5.9e-06	4.79e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—STK11—uterine cancer	5.89e-06	4.79e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP19A1—uterine cancer	5.89e-06	4.79e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—MTHFR—uterine cancer	5.87e-06	4.77e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KRAS—uterine cancer	5.82e-06	4.73e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—uterine cancer	5.8e-06	4.72e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EP300—uterine cancer	5.8e-06	4.72e-05	CbGpPWpGaD
Imatinib—KIT—Disease—PIK3CA—uterine cancer	5.79e-06	4.71e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—uterine cancer	5.78e-06	4.7e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CTNNB1—uterine cancer	5.76e-06	4.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—uterine cancer	5.75e-06	4.67e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTEN—uterine cancer	5.75e-06	4.67e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—uterine cancer	5.67e-06	4.61e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.67e-06	4.61e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTEN—uterine cancer	5.62e-06	4.57e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CTNNB1—uterine cancer	5.58e-06	4.54e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP19A1—uterine cancer	5.55e-06	4.52e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—STK11—uterine cancer	5.55e-06	4.52e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—uterine cancer	5.53e-06	4.5e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL2—uterine cancer	5.53e-06	4.5e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP19A1—uterine cancer	5.5e-06	4.48e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—STK11—uterine cancer	5.5e-06	4.48e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—uterine cancer	5.49e-06	4.47e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EP300—uterine cancer	5.48e-06	4.46e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—uterine cancer	5.48e-06	4.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	5.45e-06	4.43e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTEN—uterine cancer	5.44e-06	4.42e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—NRAS—uterine cancer	5.43e-06	4.41e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.4e-06	4.4e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—RRM2—uterine cancer	5.4e-06	4.39e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—uterine cancer	5.37e-06	4.37e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—uterine cancer	5.36e-06	4.36e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EP300—uterine cancer	5.36e-06	4.36e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—uterine cancer	5.35e-06	4.35e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—uterine cancer	5.35e-06	4.35e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—uterine cancer	5.32e-06	4.33e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	5.32e-06	4.33e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—DCN—uterine cancer	5.24e-06	4.26e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—uterine cancer	5.21e-06	4.24e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—uterine cancer	5.2e-06	4.23e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—uterine cancer	5.19e-06	4.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EP300—uterine cancer	5.19e-06	4.22e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.17e-06	4.2e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NRAS—uterine cancer	5.13e-06	4.17e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—uterine cancer	5.12e-06	4.17e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—uterine cancer	5.12e-06	4.16e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—uterine cancer	5.07e-06	4.12e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—uterine cancer	5.05e-06	4.11e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	5.03e-06	4.09e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NRAS—uterine cancer	5.01e-06	4.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—uterine cancer	4.95e-06	4.02e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—uterine cancer	4.94e-06	4.02e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	4.93e-06	4.01e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.93e-06	4.01e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—uterine cancer	4.91e-06	4e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	4.9e-06	3.99e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—uterine cancer	4.89e-06	3.98e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NRAS—uterine cancer	4.85e-06	3.95e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—uterine cancer	4.85e-06	3.94e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—uterine cancer	4.82e-06	3.92e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—uterine cancer	4.73e-06	3.85e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—uterine cancer	4.73e-06	3.85e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—STK11—uterine cancer	4.7e-06	3.83e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP19A1—uterine cancer	4.7e-06	3.83e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EP300—uterine cancer	4.67e-06	3.8e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—uterine cancer	4.67e-06	3.8e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	4.66e-06	3.79e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—uterine cancer	4.61e-06	3.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—uterine cancer	4.57e-06	3.71e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—uterine cancer	4.56e-06	3.71e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—uterine cancer	4.54e-06	3.69e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—uterine cancer	4.53e-06	3.68e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—uterine cancer	4.52e-06	3.68e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—uterine cancer	4.52e-06	3.67e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—uterine cancer	4.51e-06	3.67e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—uterine cancer	4.48e-06	3.64e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.45e-06	3.62e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—uterine cancer	4.43e-06	3.6e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	4.43e-06	3.6e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.42e-06	3.59e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—uterine cancer	4.41e-06	3.59e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—uterine cancer	4.38e-06	3.56e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—uterine cancer	4.37e-06	3.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	4.37e-06	3.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—uterine cancer	4.37e-06	3.55e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—EP300—uterine cancer	4.35e-06	3.53e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—uterine cancer	4.31e-06	3.51e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—EP300—uterine cancer	4.31e-06	3.5e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—EP300—uterine cancer	4.3e-06	3.5e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—uterine cancer	4.29e-06	3.49e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—uterine cancer	4.27e-06	3.47e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—uterine cancer	4.26e-06	3.46e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.21e-06	3.42e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—uterine cancer	4.2e-06	3.42e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—uterine cancer	4.18e-06	3.4e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—EP300—uterine cancer	4.17e-06	3.4e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—uterine cancer	4.17e-06	3.39e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—uterine cancer	4.14e-06	3.36e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—uterine cancer	4.05e-06	3.3e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—uterine cancer	4.03e-06	3.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—uterine cancer	4.03e-06	3.28e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—EP300—uterine cancer	4.01e-06	3.26e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4e-06	3.25e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—uterine cancer	4e-06	3.25e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—uterine cancer	3.97e-06	3.23e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—uterine cancer	3.96e-06	3.22e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—uterine cancer	3.93e-06	3.2e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—uterine cancer	3.92e-06	3.19e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—uterine cancer	3.84e-06	3.12e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	3.76e-06	3.06e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—uterine cancer	3.75e-06	3.05e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EP300—uterine cancer	3.75e-06	3.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—uterine cancer	3.71e-06	3.02e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—uterine cancer	3.67e-06	2.98e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.65e-06	2.96e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—STK11—uterine cancer	3.63e-06	2.95e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.63e-06	2.95e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—uterine cancer	3.55e-06	2.89e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—uterine cancer	3.55e-06	2.89e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—uterine cancer	3.53e-06	2.87e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRAS—uterine cancer	3.51e-06	2.85e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—uterine cancer	3.51e-06	2.85e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	3.46e-06	2.81e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—uterine cancer	3.34e-06	2.72e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—uterine cancer	3.31e-06	2.69e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—uterine cancer	3.26e-06	2.65e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—uterine cancer	3.24e-06	2.63e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—uterine cancer	3.21e-06	2.61e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	3.2e-06	2.6e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—uterine cancer	3.19e-06	2.59e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—uterine cancer	3.18e-06	2.59e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—uterine cancer	3.13e-06	2.55e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.12e-06	2.53e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—EP300—uterine cancer	3.11e-06	2.53e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—uterine cancer	3.09e-06	2.51e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—uterine cancer	3.02e-06	2.46e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—uterine cancer	2.96e-06	2.41e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	2.82e-06	2.3e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—uterine cancer	2.81e-06	2.29e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—uterine cancer	2.77e-06	2.26e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—uterine cancer	2.73e-06	2.22e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—uterine cancer	2.68e-06	2.18e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—EP300—uterine cancer	2.68e-06	2.18e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—uterine cancer	2.63e-06	2.14e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—uterine cancer	2.6e-06	2.12e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—uterine cancer	2.6e-06	2.11e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—uterine cancer	2.57e-06	2.09e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—uterine cancer	2.52e-06	2.05e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—uterine cancer	2.52e-06	2.05e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—uterine cancer	2.46e-06	2e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—uterine cancer	2.42e-06	1.97e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—EP300—uterine cancer	2.41e-06	1.96e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—EP300—uterine cancer	2.35e-06	1.91e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—uterine cancer	2.32e-06	1.89e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.3e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—uterine cancer	2.3e-06	1.87e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—uterine cancer	2.27e-06	1.84e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—EP300—uterine cancer	2.21e-06	1.8e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—EP300—uterine cancer	2.19e-06	1.78e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—uterine cancer	1.98e-06	1.61e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—uterine cancer	1.97e-06	1.6e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—uterine cancer	1.88e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—EP300—uterine cancer	1.88e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.78e-06	1.45e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—uterine cancer	1.74e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.64e-06	1.33e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.62e-06	1.32e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—uterine cancer	1.62e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—uterine cancer	1.52e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—uterine cancer	1.45e-06	1.18e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—EP300—uterine cancer	1.45e-06	1.18e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—uterine cancer	1.42e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.39e-06	1.13e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—uterine cancer	1.34e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—uterine cancer	1.33e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—uterine cancer	1.13e-06	9.22e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.07e-06	8.71e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—uterine cancer	8.75e-07	7.11e-06	CbGpPWpGaD
